Selection of heparin-sensitive dengue virus variants in BHK-21 cells;Selección de variantes de virus dengue sensibles a la heparina en células BHK-21

Investigacion Clinica (Venezuela)

Volumn 55, Issue 2, 2014, Pages 155-167

  Celis, Argelia ^a,b   Moros, Zoila ^a   Gerder, Marlene ^a   Pagano, Francesca ^a   Vizzi, Esmeralda ^a   Liprandi, Ferdinando ^a  

^a Instituto Venezolano de Investigaciones Cientificas Centro de Microbiologia y Biologia Celular   (Venezuela)

^b UNIVERSIDAD DE CARABOBO   (Venezuela)

Author keywords

BHK 21 cells; Dengue virus; Heparin; Serial passages; Viral adaptation

Indexed keywords

E PROTEIN; HEPARIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; E GLYCOPROTEIN, DENGUE VIRUS TYPE 1; E GLYCOPROTEIN, DENGUE VIRUS TYPE 2; E GLYCOPROTEIN, DENGUE VIRUS TYPE 3; E-GLYCOPROTEIN, DENGUE VIRUS TYPE 1; E-GLYCOPROTEIN, DENGUE VIRUS TYPE 2; E-GLYCOPROTEIN, DENGUE VIRUS TYPE 3; GLYCOPROTEIN E, DENGUE VIRUS TYPE 4; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ADAPTATION; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL SELECTION; DENGUE VIRUS; DENGUE VIRUS 2; DENGUE VIRUS 4; HUMAN; HUMAN CELL; SEROTYPE; VIRAL ADAPTATION; VIRUS REPLICATION; AEDES; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CHLOROCEBUS AETHIOPS; CYTOLOGY; DRUG EFFECT; GENETIC SELECTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HAMSTER; KIDNEY; MESOCRICETUS; MISSENSE MUTATION; MUTATION; PHYSIOLOGY; PROTEIN BINDING; PROTEIN CONFORMATION; SEQUENCE ANALYSIS; VERO CELL LINE; VIRUS CULTURE;

AEDES; ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; DENGUE VIRUS; HEPARIN; KIDNEY; MESOCRICETUS; MODELS, MOLECULAR; MUTATION; MUTATION, MISSENSE; PROTEIN BINDING; PROTEIN CONFORMATION; RNA, VIRAL; SELECTION, GENETIC; SEQUENCE ANALYSIS, RNA; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL PLAQUE ASSAY; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 84904804229     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. TDR/WHO. Dengue: Guidelines for diagnosis, treatment, prevention and control. Geneva, Switzerland: World Health Organization (WHO) & Special Programme for the Research and Training in Tropical Diseases (TDR); 2009.
2. Ranjit S, Kissoon N. Dengue hemorrhagic fever and shock syndromes. Pediatr Crit Care Med 2011; 12(1): 90-100.
3. World Health Organization. Dengue and dengue hemorrhagic fever. Factsheet No. 117.2012. Disponible en: http://www.who.int/mediacentre/factsheets/fs117/en/index.html. Accesado 13 de julio de 2012.
4. Kuhn RJ, Zhang W, Rossman MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG. Structure of Dengue virus: implications for flavivirus organization, maturation and fusion. Cell 2002; 108: 717-725.
5. Normile D. Surprising new dengue virus throws a spanner in disease control efforts. Science 2013; 342(6157): 415.
6. Monath T, Heinz F. Flavivirus. In: Fields BN, Knipe DM, Howley PM, Eds.Fields Virology. Philadelphia: Lippincott-Raven Publishers; 1996. P 961-1034.
7. Rico-Hesse R. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 1990; 174(2): 479-493.
8. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cell. J Virol 2001; 75: 7769-7773.
9. Smith GW, Wright PJ. Synthesis of proteins and glycoproteins in dengue type 2 virus infected Vero and Aedes albopictus cell. J Gen Virol 1985; 66: 559-571.
10. Heinz FX. Epitope mapping of flavivirus glycoproteins. Adv Vir Res 1986; 31:103-168.
11. Lindenbach BD, Rice CM. Flaviviridae: The viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, col., Eds. Fields Virology. Philadelphia: Lippincott-Williams y Wilkins; 2001. P 991-1041.
12. Martinez-Barragan J, Del Angel RM. Identification of a putative coreceptor on Vero cells that participates in dengue 4 virus infection. J Virol 2001; 75: 7818-7827.
13. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 1997; 3: 866-871.
14. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 2002; 292:162-168.
15. Hilgard P, Stockert R. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology 2000; 32: 1069-1077.
16. Hung SL, Lee PL, Chen HW, Chen LK, Kao CL, King CC. Analysis of the steps involved in dengue entry into host cells. Virology 1999; 257:156-167.
17. De SF-Tischer PC, Talarico LB, Noseda MD, Guimaraes SMPB, Damonte E., Duarte MER. Chemical structure and antiviral activity of carrageenans from Meristiella gelidiuma gainst herpes simplex and dengue virus. Carbohydr Polym 2006; 63: 459-465.
18. Pujol CA, Ray S, Damonte EB. Antiviral activity against dengue virus of diverse classes of algal sulfated polysaccharides. Int J Biol Macromol 2012; 51(4): 412-416.
19. Talarico LB, Duarte MER, Zibetti RGM, Noseda MD, Damonte EB. An algal derived DL-galactan hybrid is an efficient preventing agent for in vitro dengue virus infection. Plant Medical 2007; 73: 1464-1468.
20. Thaisomboonsuk BK, Clayson ET, Pantuwatana S, Vaughn DW, Endy TP. Characterization of dengue-2 virus binding to surfaces of mammalian and insect cells. Am J Trop Med Hyg 2005; 72: 375-383.
21. Celis A. Papel de los glicosaminoglicanos en las interacciones tempranas de virus dengue en células susceptibles. [Tesis Doctoral]. Caracas: Instituto Venezolano de Investigaciones Científicas (IVIC); 2011.
22. Klimstra WB, Ryman KD, Johnston R. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J Virol 1998; 72:7357-7366.
23. Lee E, Hall R, Lobigs M. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J Virol 2004; 78: 8271-8280.
24. Lee E, Lobigs M. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J Virol 2002; 76: 4901-4911.
25. Mandl CW, Kroschewski H, Allison SL, Kofler R, Holzmann H, Meixner T, Heinz FX. Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J Virol 2001; 75: 5627-5637.
26. Roche RR, Alvarez M, Guzman MG, Luis M, Kouri G. Comparison of rapid centrifugation assay with conventional tissue culture method for isolation of dengue 2 virus in C6/36-HT cells. J Clin Microbiol 2000; 38: 3508-3510.
27. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semi micro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 1985; 22:250-254.
28. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673-4680.
29. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24:1596-1599.
30. Talarico LB, Damonte EB. Interference in dengue virus adsorption and uncoating by carrageenans. Virology 2007; 363: 473-485.
31. Talarico LB, Pujol C, Zibetti R, Faría P, Noseda M, Duarte M, Damonte E. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res 2005; 66: 103-110.
32. Lee E, Wright P, Davidson A, Lobigs M. Virulence attenuation of Dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J Gen Virol 2006; 87: 2791-2801.
33. Guirakhoo FZ, Zhang G, Myers BW, Johnson K, Pugachev R, Nichols N, Brown N, Lavenbook I, Draper K, Cyrek S, Lang J, Fournier C, Barrere B, Delagrave S, Monath TP. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol 2004; 78: 9998-10008.
34. Parodi AJ. Protein glucosylation and its role in protein folding. Annu Rev Biochem 2000; 69: 69-93.
35. Trombetta ES, Helenius A. Lectins as chaperones in glycoprotein folding. Curr Opin Struct Biol 1998; 8: 587-592.
36. Lee E, Leang S, Davidson A, Lobigs M. Both E protein glycans adversely affect dengue virus infectivity but are beneficial for virion release. J Virol 2010; 84: 5171-5180.
37. Cardin A, Weintraub H. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989; 9: 21-32.
38. Añez G, Men R, Eckels K, Lai CJ. Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques. J Virol 2009; 83: 10384-10394.
39. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004; 427: 313-319.